Epigenetic drugs as immunomodulators for combination therapies in solid tumors

Luca Sigalotti, Elisabetta Fratta, Sandra Coral, Michele Maio

Research output: Contribution to journalArticlepeer-review


Continuously improving knowledge of the fine mechanisms regulating cross-talk between immune cells, and of their multi-faceted interactions with cancer cells, has prompted the development of several novel immunotherapeutic strategies for cancer treatment. Among these, modulation of the host's immune system by targeting immunological synapses has shown notable clinical efficacy in different tumor types. Despite this, objective clinical responses and, more importantly, long-term survival are achieved only by a fraction of patients; therefore, identification of the mechanism(s) responsible for the differential effectiveness of immune checkpoint blockade in specific patient populations is an area of intense investigation. Neoplastic cells can activate multiple mechanisms to escape from immune control; among these, epigenetic reprogramming is emerging as a key player. Selected tumor-associated antigens, Human Leukocyte Antigens, and accessory/co-stimulatory molecules required for efficient recognition of neoplastic cells by the immune system have been shown to be epigenetically silenced or down-regulated in cancer. Consistent with the inherent reversibility of epigenetic silencing, "epigenetic" drugs, such as inhibitors of DNA methyltransferases and of histone deacetylases, can restore the functional expression of these down-regulated molecules, thus improving the recognition of cancer cells by both the innate and adaptive immune responses. This review focuses on the immunomodulatory activity of epigenetic drugs and on their proposed clinical use in novel combined chemo- immunotherapeutic regimens for the treatment of solid tumors.

Original languageEnglish
Pages (from-to)339-350
Number of pages12
JournalPharmacology and Therapeutics
Issue number3
Publication statusPublished - 2014


  • DNA methylation
  • Histone post-translational modifications
  • Immunostimulatory antibodies
  • Immunotherapy

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Epigenetic drugs as immunomodulators for combination therapies in solid tumors'. Together they form a unique fingerprint.

Cite this